Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Phase 1 Terminated

203 enrolled 43 charts

Phase 3 Active not recruiting

B-cell Malignancies

NCT04666038 2025-04-20

BRUIN CLL-321

238 enrolled 17 charts 1 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04699461 2023-10-23

LOTIS-6

6 enrolled 9 charts

Lymphoma, Lymphoma, Follicular

NCT02536300 2023-08-14

Dose Optimization Study of Idelalisib in Follicular Lymphoma

96 enrolled 22 charts

Lymphoma, Follicular

NCT02968563 2022-01-21

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

35 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02639910 2021-12-20

COSMOS

24 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02242045 2021-03-19

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Phase 1 Completed

6 enrolled 14 charts

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Completed

241 enrolled 31 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02538614 2020-11-25

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Phase 1 Terminated

2 enrolled 5 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01796470 2020-06-02

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

66 enrolled 14 charts

Leukemia, Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01569295 2020-03-10

Tugela

Phase 3 Completed

416 enrolled 16 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02739360 2020-03-04

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Phase 4 Terminated

3 enrolled 5 charts

Lymphoid Malignancies

NCT01539291 2019-08-20

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

161 enrolled 34 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01659021 2019-08-14

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

261 enrolled 21 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01282424 2019-07-11

DELTA

125 enrolled 25 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01539512 2019-05-14

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Phase 3 Completed

220 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02258529 2019-05-14

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

10 enrolled 10 charts

Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01306643 2018-11-19

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

Phase 1/2 Completed

18 enrolled 8 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01393106 2018-11-19

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

25 enrolled 22 charts

Hodgkin Disease

NCT01980875 2018-11-19

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

57 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01980888 2018-11-19

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

311 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02044822 2018-11-19

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

102 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01732926 2018-11-16

Bridalveil

475 enrolled 9 charts